| | | |   | | | | By Ed Silverman Andrew Harnik/AP The Justice Department is seeking information about activities in which Bausch Health medicines may have been promoted for unapproved uses. Read More | | By Ed Silverman Ruby Wallau for STAT The existing cost of care is “expensive enough that there are big offsets to having a one-time therapy," said David Rind of ICER. Read More | | By Adam Feuerstein Kirsty Wigglesworth/AP The deal was struck three months after Sierra’s lead drug, a treatment for the blood cancer myelofibrosis, succeeded in a late-stage trial. Read More | | Sponsor content by RARE ACCESS ACTION PROJECT Rare disease patients deserve protection from Washington politics Right now, politicians need a win, but rare disease patients could lose. In Congress' rush to pass something, therapies for rare diseases and cancers could face an increase of between 400% and 800% in Medicare Part D costs. There is a better way that protects patients. Learn more. | | By Jonathan Wosen Adobe Halozyme is pursuing a strategy that’s proven profitable — developing quick, convenient ways to deliver drugs to patients. Read More | |
No comments